CML Interactive Cases: An Immersive Simulated Learning Experience
According to the American Cancer Society, chronic myeloid leukemia (CML) accounts for 15 to 20 percent of leukemias in adults. Management options for patients with CML include disease control using tyrosine kinase inhibitors, potential cure with allogeneic hematopoietic cell transplantation (HCT), and palliative therapy with cytotoxic agents. Among the factors that may inform treatment choice are phase of CML, patient age, presence of comorbidities, donor availability for HCT, and response to treatment with tyrosine kinase inhibitors.
This educational activity provides an opportunity to explore two different CML cases. Learners will navigate treatment decisions based on patient presentation, history, and other findings that may impact the therapeutic approach.
ASH thanks Pfizer for their support of this program.
I’m Ready to Start a Family and You’re Telling Me I Have Leukemia?!
Navigating Loss of Response to First-Line Treatment for CML
- Apply relevant information on new treatment developments appropriately to regimen/clinical trial selection
- Use timely and complete risk stratification and safety/tolerability risk assessment findings to inform treatment selection
- Explain defined milestones and related monitoring parameters that can inform optimal treatment choice
- Identify strategies for mitigating BCR-ABL TKI treatment nonadherence
Hematologists, oncologists, and other health care professionals involved in the care and treatment of patients with CML.
Jessica Altman, MD
Northwestern University, Chicago, IL
Consultancy: Syros; Celgene; Astellas; Immune Pharmaceuticals; Janssen Pharmaceuticals; Novartis
Other: ASH, Educational Speaker; NCCN, Educational Speaker; Hemedicus, Advisor to CME Company
Elizabeth Hexner, MD, MS
University of Pennsylvania, Philadelphia, PA
Research Funding: Novartis
Membership on a Board or Advisory Committee: Novartis
Jorge Cortes, MD
MD Anderson Cancer Center, Houston, TX
Consultancy: Ariad; Astellas; Biopath Holdings; BMS; Imunogen; Jazz; Novartis; Pfizer
Research Funding: Ariad; Ambit Biosciences; Astellas;Bristol-Myers Squibb; BMS; ChemGenex;Immunogen; Jazz; Novartis; Pfizer; Targegen; Teva; Wyeth
Membership on a Board or Advisory Committee: ChemGenex
Kendra Sweet, MD
Moffitt Cancer Center, Tampa, FL
Consultancy: Amgen; Astra Zeneca; Celgene; Gilead; Hospira; Pharmacyclics; Roche/Genentech; Sandoz; Takeda;
Research Funding: Karyopharm; The Leukemia and Lymphoma Society
Speakers Bureau: Ariad; Celgene; Novartis Membership on a Board or Advisory Committee: Ariad; Novartis; Otsuka; Pfizer
Ehab Atallah, MD
Medical College of Wisconsin, Milwaukee, WI
Jason Gotlib, MD, MS
Stanford University, Stanford, CA
Date of release
May 21, 2018
Date of expiration
Online access expiration and last date for learners to claim CME/MOC credit for this activity: May 21, 2019
Accreditation and Credit Designation
The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
ASH designates this internet enduring material for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who participate in this CME activity but are not licensed in the United States are also eligible for AMA PRA Category 1 Credit™.
ABIM Maintenance of Certification Points
Successful completion of this CME activity enables the participant to earn up to 5.0 Maintenance of Certification (MOC) points in the ABIM MOC program. Participants earn MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant completion information to the Accreditation Council for Continuing Medical Education (ACCME) for the purpose of granting ABIM MOC credit.
Claiming CME and ABIM Credit
The estimated time to complete this educational activity, comprised of two interactive cases, is 5.0 hours. To claim CME credit, learners must complete the post-test(s) of medical knowledge and an activity evaluation for each interactive case completed. Evaluation modules can be accessed upon completion of corresponding cases.
Learners who pass the post-tests are eligible to claim credit for the activity. The learner is allowed multiple attempts to pass the post-test for each interactive case. Successful completion of each test earns the learner a portion of the total 5.0 credit hours. Learners claim CME and/or MOC credit for each test individually.
CML Interactive Cases: An Immersive Simulated Learning Experience
|Case 1: I’m Ready to Start a Family and You’re Telling Me I Have Leukemia?!||2.5|
|Case 2: Navigating Loss of Response to First-Line Treatment for CML||2.5|
On May 21, 2019, online access expires. This is also the last date for users to claim credit for this activity.
For questions about credit, please contact the ASH Education Department at email@example.com or call toll-free 866-828-1231 (within the United States only).
The following resources have been identified as relevant to health care professionals involved in the care and treatment of patients with CML.
Monitoring Response in CML
Perspectives on Treatment-Free Remission
Selected Literature and Guidelines
Baccarani M, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23803709
Barber MC, et al. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017;2017(1):110-114. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29222244
Branford S. Monitoring and defining early response: where to draw the line? Best Pract Res Clin Haematol. 2016;29(3):284-294. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27839569
Egan D, Radich J. Making the diagnosis, the tools, and risk stratification: more than just BCR-ABL. Best Pract Res Clin Haematol. 2016;29(3):252-263. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27839566
Hochhaus A, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(s4):iv41-iv51. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28881915
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442-459. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29411417
Mahon FX. Treatment-free remission in CML: who, how, and why? Hematology Am Soc Hematol Educ Program. 2017;2017(1):102-109. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29222243
NCCN Chronic Myeloid Leukemia: January 24, 2018;version 4. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
NCCN Guidelines for Patients: 2018. Available at: https://www.nccn.org/patients/guidelines/cml/